SFM
TRIL

Sphera Funds Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Sphera Funds Management’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-670,459
Closed -$7.2M – 205
2021
Q1 		$7.2M Buy
670,459
+43,700
+7% +$540K 0.55% 53
2020
Q4 		$9.22M Sell
626,759
-18,676
-3% -$269K 0.82% 34
2020
Q3 		$9.17M Sell
645,435
-532,911
-45% -$5.31M 0.9% 29
2020
Q2 		$9.53M Sell
1,178,346
-82,348
-7% -$509K 0.9% 29
2020
Q1 		$5.09M Buy
+1,260,694
New +$4.77M 0.64% 33
2016
Q4 		– Sell
-132,300
Closed -$1.96M – 126
2016
Q3 		$1.96M Hold
132,300
– – 0.32% 74
2016
Q2 		$1.19M Hold
132,300
– – 0.31% 74
2016
Q1 		$1.22M Hold
132,300
– – 0.27% 75
2015
Q4 		$1.67M Sell
132,300
-14,700
-10% -$204K 0.24% 93
2015
Q3 		$1.92M Hold
147,000
– – 0.24% 98
2015
Q2 		$3.21M Buy
147,000
+52,000
+55% +$1.19M 0.31% 80
2015
Q1 		$1.92M Buy
+95,000
New +$1.4M 0.2% 107

Other funds holding TRIL

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Sphera Funds Management's TRIL Position: Q2 2021 in Review

Sphera Funds Management sold out of Trillium Therapeutics Inc. (TRIL) in Q2 2021, closing a stake of 670,459 shares — an estimated $7.2M sold.

Sphera Funds Management first reported a position in TRIL in Q1 2015 and held it in 12 quarters. The position peaked at $9.53M in Q2 2020. 137 funds tracked by Wall St. Rank hold TRIL as of Q2 2021.

  • Sphera Funds Management reported no remaining Trillium Therapeutics Inc. position as of Q2 2021 after selling out during the quarter.
  • Sphera Funds Management sold 670,459 Trillium Therapeutics Inc. shares in Q2 2021, an estimated $7.2M.
  • Sphera Funds Management first reported a position in Trillium Therapeutics Inc. in Q1 2015 and held it in 12 quarters.
  • Sphera Funds Management's Trillium Therapeutics Inc. position peaked at $9.53M in Q2 2020.
  • 137 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q2 2021.

Based on Sphera Funds Management's 13F filing for Q2 2021, filed 17 Aug 2021.